These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 24904434)

  • 1. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.
    Brisch R; Saniotis A; Wolf R; Bielau H; Bernstein HG; Steiner J; Bogerts B; Braun K; Jankowski Z; Kumaratilake J; Henneberg M; Gos T
    Front Psychiatry; 2014; 5():47. PubMed ID: 24904434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia.
    Zuo D; Bzdega T; Olszewski RT; Moffett JR; Neale JH
    J Biol Chem; 2012 Jun; 287(26):21773-82. PubMed ID: 22570482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinergic systems and schizophrenia: primary pathology or epiphenomena?
    Hyde TM; Crook JM
    J Chem Neuroanat; 2001 Jul; 22(1-2):53-63. PubMed ID: 11470554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the central cholinergic system in the therapeutics of schizophrenia.
    Terry AV
    Curr Neuropharmacol; 2008 Sep; 6(3):286-92. PubMed ID: 19506725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemistry and the schizophrenia. Old concepts and new hypothesis.
    Berger PA
    J Nerv Ment Dis; 1981 Feb; 169(2):90-9. PubMed ID: 7009786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia.
    Jentsch JD; Roth RH
    Neuropsychopharmacology; 1999 Mar; 20(3):201-25. PubMed ID: 10063482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroanatomical, neurochemical, and neurodevelopmental basis of obsessive-compulsive symptoms in schizophrenia.
    Venkatasubramanian G; Rao NP; Behere RV
    Indian J Psychol Med; 2009 Jan; 31(1):3-10. PubMed ID: 21938084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia.
    Wang H; Xu J; Lazarovici P; Quirion R; Zheng W
    Front Mol Neurosci; 2018; 11():255. PubMed ID: 30214393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].
    Maćkowiak M; Czyrak A; Wedzony K
    Psychiatr Pol; 2000; 34(4):607-21. PubMed ID: 11059260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine in schizophrenia: a review and reconceptualization.
    Davis KL; Kahn RS; Ko G; Davidson M
    Am J Psychiatry; 1991 Nov; 148(11):1474-86. PubMed ID: 1681750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamines and schizophrenia.
    Sedvall G
    Acta Psychiatr Scand Suppl; 1990; 358():7-13. PubMed ID: 1978495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders.
    Nikolaus S; Antke C; Müller HW
    Behav Brain Res; 2009 Dec; 204(1):32-66. PubMed ID: 19523495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia.
    Abi-Dargham A; Moore H
    Neuroscientist; 2003 Oct; 9(5):404-16. PubMed ID: 14580124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neurobiology of schizophrenia.
    Littrell RA; Schneiderhan M
    Pharmacotherapy; 1996; 16(6 Pt 2):143S-147S; discussion 166S-168S. PubMed ID: 8947997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered Excitatory-Inhibitory Balance in the NMDA-Hypofunction Model of Schizophrenia.
    Kehrer C; Maziashvili N; Dugladze T; Gloveli T
    Front Mol Neurosci; 2008; 1():6. PubMed ID: 18946539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis.
    Yang AC; Tsai SJ
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28771182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurochemical imaging in schizophrenia.
    Urban N; Abi-Dargham A
    Curr Top Behav Neurosci; 2010; 4():215-42. PubMed ID: 21312402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dreaming and schizophrenia: a common neurobiological background?].
    Gottesmann C
    Med Sci (Paris); 2006 Feb; 22(2):201-5. PubMed ID: 16457764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.